Publication
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerDiffuse Large B-Cell Lymphoma Germinal Center B-Cell Typecivic_curation1.00
- cancerFollicular Lymphomacivic_curation1.00
- drugTazemetostatcivic_curation1.00
- geneEZH2civic_curation1.00
- variantEZH2 Activating Mutationcivic_curation1.00
- variantEZH2 expressioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 33492746
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EZH2 expression1 | ||||||||
| Tazemetostat | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID11108In this phase I study (clinical trial NCT03009344), one patient with germinal center B‐cell‐like (GCB) DLBCL and two with non-GCB DLBCL types were recruited to test the efficacy of EZH2 inhibitor-Taze… (full text at CIViC) PMID 33492746 · Munakata et al., 2021 · Open in CIViC | civic |
| EZH2 Activating Mutation1 | ||||||||
| Tazemetostat | Follicular Lymphoma | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID11107In this phase I study, four Japanese patients with follicular lymphoma were recruited to test the efficacy of EZH2 inhibitor-Tazemetostat. Patients were screened for presence of EZH2 mutations and onl… (full text at CIViC) PMID 33492746 · Munakata et al., 2021 · Open in CIViC | civic |